|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, NOX4 and Nrf2 may be promising combination targets against malignant progression of NSCLC.
|
28196727 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Nrf2, a redox-sensing transcription factor, on constitutive activation in non-small-cell lung cancer cells upregulates a wide spectrum of genes involved in redox balance, glutathione metabolism, and drug detoxification, which contribute to chemoresistance and tumorigenicity.
|
20682644 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Non-small cell lung cancer (NSCLC) cells often possess a hypermethylated Keap1 promoter, which decreases Keap1 mRNA and protein expression levels, thus impairing the Nrf2-Keap1 pathway and thereby leading to chemo- or radio-resistance.
|
27029077 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
|
17020408 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together, our results indicate that the Nestin-Keap1-Nrf2 axis regulates cellular redox homeostasis and confers oxidative stress resistance in NSCLC.
|
31695040 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Collectively, mutant p53 may confer cisplatin resistance via upregulation of Nrf2 expression, and Nrf2 mRNA level may predict chemotherapeutic response and outcomes in NSCLC.
|
26497680 |
2015 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Finally, we report that NRF2 protein expression in a NSCLC cohort exceeds the typical incidence of combined NRF2, KEAP1, and CUL3 mutations, and that NRF2 expression in this cohort is correlated with PIDD levels.
|
31455821 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Previous studies suggest that Nrf2 may be constitutively activated in NSCLC.
|
17606720 |
2007 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We examined the usefulness of Nrf2 and NQO1 as indicators of prognosis in NSCLC.
|
28501854 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We demonstrate the discovery and validation of ML385 as a novel and specific NRF2 inhibitor and conclude that targeting NRF2 may represent a promising strategy for the treatment of advanced NSCLC.
|
27552339 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Loss of function mutations in the Nrf2 inhibitor, Kelch-like ECH-associated protein (Keap1), results in constitutive activation of Nrf2 function in non-small cell lung cancer.
|
18829555 |
2008 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our results further suggest that deregulation of the NRF2/KEAP1 system could play a pivotal role in the cancerogenesis of NSCLC.
|
21610322 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Nrf2 is often constitutively activated in non-small cell lung cancer (NSCLC) cell lines, which promotes cytoprotection against oxidative stress and xenobiotics.
|
26691854 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
High levels of Nrf2, resulting from a loss of function mutation in Keap1, were reported in chemoresistant non-small cell lung cancer.
|
19940992 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
TP53 and NFE2L2 mutations were observed more frequently in advanced NSCLC stages.
|
27161973 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The transcription factor NRF2 is a master regulator of the cellular antioxidant response, and it is often genetically activated in non-small-cell lung cancers (NSCLCs) by, for instance, mutations in the negative regulator KEAP1.
|
28965760 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Together, our findings demonstrated that luteolin inhibits the Nrf2 pathway in vivo and can serve as an adjuvant in the chemotherapy of NSCLC.
|
24747074 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
LAPTM4B is associated with poor prognosis in NSCLC and promotes the NRF2-mediated stress response pathway in lung cancer cells.
|
26343532 |
2015 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here we show that Nrf2-mediated NSCLC cell proliferation is dually regulated by epidermal growth factor receptor (EGFR) signaling and an Nrf2 repressor protein Keap1 (Kelch-like ECH-associated protein-1).
|
22249257 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Both Nrf2 overexpression and Beclin1 lower-expression are independent indicators of a poor prognosis in NSCLC patients.
|
30160218 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this study, the increased copy number of the NRF2 gene was analyzed by real-time polymerase chain reaction (real-time-PCR) amplifications in 90 surgically-treated non-small cell lung cancer (NSCLC) cases.
|
22614957 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Increased Nrf2 concentration resulting from loss of function Keap1 mutations has been described in chemoresistant non-small cell lung cancer.
|
19638449 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Unexpectedly, stable knockdown of KEAP1 by lentiviral shRNA sensitized three independent NSCLC cell lines (A549, HTB-178, and HTB-182) to multiple chemotherapeutic agents, including arsenic trioxide (As(2)O(3)), etoposide, and doxorubicin, despite moderately increased NRF2 levels.
|
22684020 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study demonstrates that the NRF2 pathway may serve as a therapeutic target in NSCLC, and ginseng compounds may be effective for the treatment of this disease.
|
31415285 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Molecular characterization studies revealed recurrent kelch like ECH associated protein 1 gene (KEAP1)/nuclear factor, erythroid 2 like 2 gene (NFE2L2) alterations in NSCLC.
|
31323387 |
2019 |